The Broad Anti-AML Activity of the CD33/CD3 BiTE Antibody Construct, AMG 330, Is Impacted by Disease Stage and Risk.
The CD33/CD3-bispecific T-cell engaging (BiTE) antibody construct, AMG 330, potently lyses CD33+ leukemic cells in vitro. Using specimens from 41 patients with acute myeloid leukemia (AML), we studied the factors that might contribute to clinical response or resistance. For this purpose, thawed aliq...
Main Authors: | Kimberly H Harrington, Chelsea J Gudgeon, George S Laszlo, Kathryn J Newhall, Angus M Sinclair, Stanley R Frankel, Roman Kischel, Guang Chen, Roland B Walter |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2015-01-01
|
Series: | PLoS ONE |
Online Access: | http://europepmc.org/articles/PMC4549148?pdf=render |
Similar Items
-
CD33/CD3-bispecific T-cell engaging (BiTE®) antibody construct targets monocytic AML myeloid-derived suppressor cells
by: Regina Jitschin, et al.
Published: (2018-11-01) -
ABSENT CD33 IN AML PATIENTS: FROM DIAGNOSIS TO FOLLOW-UPS
by: Leticia O. Marani, et al.
Published: (2023-04-01) -
Evaluation The Role of CD33+ CD11b+ myeloid-derived Suppressor Cells in Patients With AML
by: Hala Hamad, et al.
Published: (2022-07-01) -
ABSENT CD33 IN AML PATIENT MIMICS MRD POSITIVE: A SINGLE CASE REPORT
by: LO Marani, et al.
Published: (2021-10-01) -
33 Development of a clinical ex vivo assay for the assessment of therapeutic CD28 costimulatory pathway engagement
by: Jing Yang, et al.
Published: (2021-11-01)